Stanley Capital Partners LLP (SCP), the European and US-focused mid-market private equity firm, today announced the acquisition of MyMeds&Me Limited (MMM) by its portfolio company Drug Safety and Pharmacovigilance Services Solutions (DSS). DSS is a leading global provider of pharmacovigilance services under the brand Bioclinica. The financial terms of the transaction are not being disclosed.
UK-headquartered, MyMeds&Me capture safety data directly from patients, healthcare professionals and Pharma teams across multiple intake channels through its global SaaS platform, Reportum®. MMM has a broad, well-established, and global client base, which includes some of the world’s leading pharmaceutical companies.
The combined, digital-first organisation will provide a best-in-class pharmacovigilance solution focused on the current and future requirements of the life sciences industry.
Embracing a digital-first approach will enable DSS to be the foremost provider of pharmacovigilance services, leveraging Reportum for the capture and management of relevant data, supported by the highest calibre of medical and scientific staff.
This strategy will also accelerate the development of the Reportum platform to enhance its inherent capabilities and provide seamless integrations with other solutions in the technology landscape, both pre- and post-approval. Together, DSS and MMM will provide the industry with a dynamic offering that encompasses a compelling technology roadmap and world-class services to meet customer portfolio and business requirements.
“The acquisition of MMM will give a further boost to the high-quality service offering we are delivering to our clients, which include some of the world’s largest and most innovative pharmaceutical companies, with the support and investment of SCP.” said Humaira Qureshi, CEO of DSS. “The acquisition aligns with the shared strategy of DSS and SCP to secure M&A transactions that grow the technology-enabled platform and broaden the client-focused service offering.”
“MyMeds&Me is proud to be joining the DSS family, providing us with a framework to expand our high-quality technology offering. With the industry’s ever greater focus on patient engagement, the deployment of innovative technology combined with complementary services from DSS will enable our customers to revolutionise their pharmacovigilance strategy and optimise the safe use of their medicines.” said Dr Andrew Rut, CEO and founder of MMM.
“SCP’s overall strategy of ensuring DSS remains at the forefront of specialist service provision is supported by this acquisition,” said SCP Founding Partner, Simon Cottle. “We look forward to supporting DSS and MMM in building innovative technology to navigate the rapidly evolving landscape of pharmacovigilance. This state-of-the-art software will support the industry in accommodating higher volumes of data and heightened patient awareness regarding drug safety.”
About Stanley Capital Partners LLP
Stanley Capital Partners LLP (SCP) is a European and US-focused mid-market private equity firm using research and technology to identify opportunities in the growing sustainable investment sectors of Resource Efficiency, Healthcare and Technology. SCP targets businesses with Enterprise Values of $250mn to $2.5bn or more. In majority and minority transactions, SCP partners with management teams to transform companies through growth via technology and operational change and market consolidation. SCP was founded in 2019 by Simon Cottle, James Brooks and Patrick Hargutt and has a team of 10 professionals working closely together with its Leader Network and investor, sector and technology partners. DSS represents the 4th investment that SCP has led since its formation in 2019, evidencing SCP’s strong ability to originate investment opportunities and deploy capital.
DSS is headquartered in the UK and has deep expertise and experience from early phase studies to marketed products. DSS has mastered collecting the reliable evidence needed to bring new drugs and therapies to market. DSS uses technology and medically qualified professionals to support clients in their current state while planning for your strategic objectives. Their PV SMEs, comprised of both physicians and scientists are end-to-end partners for our clients, proactively advising and collaborating in designing and maintaining PV services and systems which are fit-for-future.
MyMeds&Me was founded in 2012 by Pharma industry experts. The company provides an end-to-end pharmacovigilance solution, Reportum®, to standardise adverse event and product quality data capture across all intake routes and accelerate safety insights. Reportum is a proven, scalable drug safety platform, in high volume use by Pharma & CROs around the world.